Table 3.
General characteristics of bortezomib chemotherapy response-annotated MM datasets.
| Reference | Dataset ID | Therapy | Experimental platform | Number N of cases (R vs NR) | Number of core marker genes |
|---|---|---|---|---|---|
| Current study (full cohort) | Bortezomib, doxorubicin, dexamethasone (PAD) AND/OR bortezomib, cyclophosphamide, dexamethasone (VCD) | RNA sequencing, Illumina HiSeq 3000 | 53 (28 R: complete response + very good partial response; 25 NR: partial response + minimal response) | 8 | |
| Current_Study_VCD | Bortezomib, cyclophosphamide, dexamethasone (VCD) | RNA sequencing, Illumina HiSeq 3000 | 47 (24 R: complete response + very good partial response; 23 NR: partial response + minimal response) | 10 | |
| (25) | GSE9782 | Bortezomib monotherapy | Affymetrix Human Genome U133 Array | 169 (85 R: complete response + partial response; 84 NR: no change + progressive disease) | 18 |
| (29) | GSE68871 | Bortezomib-thalidomide-dexamethasone | Affymetrix Human Genome U133 Plus | 118 (69 R: complete, near-complete and very good partial responders; 49 NR: partial, minor and worse) | 12 |
| (27) | GSE55145 | Bortezomib followed by ASCT | Affymetrix Human Exon 1.0 ST Array | 61 (33 R: complete, near-complete and very good partial responders; 28 R: partial, minor and worse) | 14 |
| (32, 41) | GSE19784_1 | Bortezomib, doxorubicin, dexamethasone (PAD) | Affymetrix Human Genome U133 Plus 2.0 Array | 61 with ISS stage I [32 R, 29 NR (32)] | 7 |
| (32, 41) | GSE19784_2 | Bortezomib, doxorubicin, dexamethasone (PAD) | Affymetrix Human Genome U133 Plus 2.0 Array | 51 with ISS stage II [33 R, 18 NR (32)] | 12 |
| (32, 41) | GSE19784_3 | Bortezomib, doxorubicin, dexamethasone (PAD) | Affymetrix Human Genome U133 Plus 2.0 Array | 41 with ISS stage III [29 R, 12 NR (32)] | 11 |
| (32, 34) | GSE2658 | Bortezomib, doxorubicin, dexamethasone (PAD) | Affymetrix Human Genome U133 Plus 2.0 Array | 208 [55 R, 153 NR (32)] | 16 |